Jci_page_head_homepage_01 Jci_page_head_homepage_02
Laura A. Napolitano, Diane Schmidt, Michael B. Gotway, Niloufar Ameli, Erin L. Filbert, Myra M. Ng, Julie L. Clor, Lorrie Epling, Elizabeth Sinclair, Paul D. Baum, Kai Li, Marisela Lua Killian, Peter Bacchetti, Joseph M. McCune
Published in Volume 118, Issue 3
J Clin Invest. 2008; 118(3):1085–1098 doi:10.1172/JCI32830
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 6
Increases in circulating IGF-1 are associated with immunologic changes in GH-treated HIV-1–infected adults.

Regression analysis data revealed that changes in naive and total CD4+ T cells (C), activated CD8+CD38+DR+ cells (D), and circulating IL-7 levels (E) are associated with GH-induced increases in IGF-1. (B) Higher levels of IGF-1 appear to increase the frequency of PBMC TRECs but decrease the frequency of naive T cell TRECs. (A) GH treatment increased thymic density regardless of IGF-1 gain; however, higher gains in IGF-1 were associated with increased thymic volume. These results suggest that IGF-1 mediates several GH effects on the human immune system. Estimated changes with 95% CIs are shown. Analysis estimated the effects of 1 year of GH. *P < 0.05 for indicated comparisons.